Answer
No, Keytruda (pembrolizumab) has not been studied in patients with severe renal impairment.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.2 Posology and method of administration · Version 64Document updated
Sources checked